Krister Wennerberg

Krister Wennerberg

Professor

Member of:

    ORCID: 0000-0002-1352-4220

    Publication year:
    All
    41 - 50 out of 122Page size: 10
    Sort by: 1st author

    1. Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients

      He, L., Tang, J., Andersson, E. I., Timonen, S., Koschmieder, S., Wennerberg, Krister, Mustjoki, S. & Aittokallio, T., 1 May 2018, In: Cancer Research. 78, 9, p. 2407-2418 12 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    2. Published

      Atypical KRASG12R mutant is impaired in PI3K signaling and macropinocytosis in pancreatic cancer

      Hobbs, G. A., Baker, N. M., Miermont, A. M., Thurman, R. D., Pierobon, M., Tran, T. H., Anderson, A. O., Waters, A. M., Diehl, J. N., Papke, B., Hodge, R. G., Klomp, J. E., Goodwin, C. M., DeLiberty, J. M., Wang, J., Ng, R. W. S., Gautam, P., Bryant, K. L., Esposito, D., Campbell, S. L. & 8 others, Petricoin, E. F., Simanshu, D. K., Aguirre, A. J., Wolpin, B. M., Wennerberg, Krister, Rudloff, U., Cox, A. D. & Der, C. J., 2020, In: Cancer Discovery. 10, 1, p. 104-123 20 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    3. Toward universal protein post-translational modification detection in high throughput format

      Härmä, H., Tong-Ochoa, N., van Adrichem, A. J., Jelesarov, I., Wennerberg, Krister & Kopra, K., 2018, In: Chemical communications (Cambridge, England). 54, 23, p. 2910-2913 4 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    4. Published

      Prediction of drug combination effects with a minimal set of experiments

      Ianevski, A., Giri, A. K., Gautam, P., Kononov, A., Potdar, S., Saarela, J., Wennerberg, Krister & Aittokallio, T., 2019, In: Nature Machine Intelligence. 1, 12, p. 568-577

      Research output: Contribution to journal › Journal article › Research › peer-review

    5. Published

      Patient-tailored design for selective co-inhibition of leukemic cell subpopulations

      Ianevski, A., Lahtela, J., Javarappa, K. K., Sergeev, P., Ghimire, B. R., Gautam, P., Vähä-Koskela, M., Turunen, L., Linnavirta, N., Kuusanmäki, Heikki Aleksi, Kontro, M., Porkka, K., Heckman, C. A., Mattila, P., Wennerberg, Krister, Giri, A. K. & Aittokallio, T., 2021, In: Science Advances. 7, 8, eabe4038.

      Research output: Contribution to journal › Journal article › Research › peer-review

    6. Seed-effect modeling improves the consistency of genome-wide loss-of-function screens and identifies synthetic lethal vulnerabilities in cancer cells

      Jaiswal, A., Peddinti, G., Akimov, Y., Wennerberg, Krister, Kuznetsov, S., Tang, J. & Aittokallio, T., 1 Jun 2017, In: Genome Medicine. 9, 1, p. 51

      Research output: Contribution to journal › Journal article › Research › peer-review

    7. Published

      Multi-modal meta-analysis of cancer cell line omics profiles identifies ECHDC1 as a novel breast tumor suppressor

      Jaiswal, A., Gautam, P., Pietilä, E. A., Timonen, S., Nordström, N., Akimov, Y., Sipari, N., Tanoli, Z., Fleischer, T., Lehti, K., Wennerberg, Krister & Aittokallio, T., 2021, In: Molecular Systems Biology. 17, 3, p. 1-25 e9526.

      Research output: Contribution to journal › Journal article › Research › peer-review

    8. Published

      ALDH1A1‐related stemness in high‐grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR‐PI3K/aurora kinase inhibitors

      Kaipio, K., Chen, P., Roering, P., Huhtinen, K., Mikkonen, P., Östling, P., Lehtinen, L., Mansuri, N., Korpela, T., Potdar, S., Hynninen, J., Auranen, A., Grénman, S., Wennerberg, Krister, Hautaniemi, S. & Carpén, O., 2020, In: Journal of Pathology. 250, 2, p. 159-169 10 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    9. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML

      Karjalainen, R., Pemovska, T., Popa, M., Liu, M., Javarappa, K. K., Majumder, M. M., Yadav, B., Tamborero, D., Tang, J., Bychkov, D., Kontro, M., Parsons, A., Suvela, M., Mayoral Safont, M., Porkka, K., Aittokallio, T., Kallioniemi, O., McCormack, E., Gjertsen, B. T., Wennerberg, K. & 2 others, Knowles, J. & Heckman, C. A., 10 Aug 2017, In: Blood. 130, 6, p. 789-802 14 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    10. Published

      PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells

      Kauko, O., O’Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., Yetukuri, L., Yadav, B., Padzik, A., Laajala, T. D., Haapaniemi, P., Momeny, M., Varila, T., Ohlmeyer, M., Aittokallio, T., Wennerberg, Krister, Narla, G. & Westermarck, J., 18 Jul 2018, In: Science Translational Medicine. 10, 450, p. 1-12 12 p., eaaq1093.

      Research output: Contribution to journal › Journal article › Research › peer-review

    Previous 1 2 3 4 5 6 7 8 ...13 Next

    ID: 181406515